Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $4.73 million. The enterprise value is $4.60 million.
| Market Cap | 4.73M |
| Enterprise Value | 4.60M |
Important Dates
The next estimated earnings date is Tuesday, November 17, 2026, after market close.
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 2.54 million shares outstanding. The number of shares has increased by 43.66% in one year.
| Current Share Class | 2.54M |
| Shares Outstanding | 2.54M |
| Shares Change (YoY) | +43.66% |
| Shares Change (QoQ) | +24.81% |
| Owned by Insiders (%) | 25.55% |
| Owned by Institutions (%) | 6.01% |
| Float | 1.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,575.10 |
| Forward PS | n/a |
| PB Ratio | 7.09 |
| P/TBV Ratio | 7.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,533.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.77, with zero debt.
| Current Ratio | 0.77 |
| Quick Ratio | 0.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -185.95% and return on invested capital (ROIC) is -117.58%.
| Return on Equity (ROE) | -185.95% |
| Return on Assets (ROA) | -81.13% |
| Return on Invested Capital (ROIC) | -117.58% |
| Return on Capital Employed (ROCE) | -622.24% |
| Weighted Average Cost of Capital (WACC) | -1.40% |
| Revenue Per Employee | $3,000 |
| Profits Per Employee | -$4.12M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.62% in the last 52 weeks. The beta is -1.03, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -1.03 |
| 52-Week Price Change | -31.62% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 2.32 |
| Relative Strength Index (RSI) | 48.81 |
| Average Volume (20 Days) | 21,609,845 |
Short Selling Information
The latest short interest is 818,602, so 32.22% of the outstanding shares have been sold short.
| Short Interest | 818,602 |
| Short Previous Month | 9,736 |
| Short % of Shares Out | 32.22% |
| Short % of Float | 68.01% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, TCRT had revenue of $3,000 and -$4.12 million in losses. Loss per share was -$1.77.
| Revenue | 3,000 |
| Gross Profit | -1.64M |
| Operating Income | -4.06M |
| Pretax Income | -4.01M |
| Net Income | -4.12M |
| EBITDA | -4.03M |
| EBIT | -4.06M |
| Loss Per Share | -$1.77 |
Balance Sheet
The company has $124,000 in cash and no debt, with a net cash position of $124,000 or $0.05 per share.
| Cash & Cash Equivalents | 124,000 |
| Total Debt | n/a |
| Net Cash | 124,000 |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 652,000 |
| Book Value Per Share | 0.26 |
| Working Capital | -198,000 |
Cash Flow
In the last 12 months, operating cash flow was -$2.73 million and capital expenditures -$98,000, giving a free cash flow of -$2.83 million.
| Operating Cash Flow | -2.73M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 23,000 |
| Net Borrowing | 70,000 |
| Free Cash Flow | -2.83M |
| FCF Per Share | -$1.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | -135,233.33% |
| Pretax Margin | -133,666.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -43.66% |
| Shareholder Yield | -43.66% |
| Earnings Yield | -95.08% |
| FCF Yield | -59.78% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 18, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
TCRT has an Altman Z-Score of -860.17 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -860.17 |
| Piotroski F-Score | 1 |